WO2005023295A3 - Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation - Google Patents

Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation Download PDF

Info

Publication number
WO2005023295A3
WO2005023295A3 PCT/NL2004/000626 NL2004000626W WO2005023295A3 WO 2005023295 A3 WO2005023295 A3 WO 2005023295A3 NL 2004000626 W NL2004000626 W NL 2004000626W WO 2005023295 A3 WO2005023295 A3 WO 2005023295A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
peptides derived
naturally processed
immunodominant peptides
neisseria meningitidis
Prior art date
Application number
PCT/NL2004/000626
Other languages
English (en)
Other versions
WO2005023295A2 (fr
Inventor
Els Cecile Antoinette Caro Van
Jong Adrianus Petrus Joseph De
Hugo Derk Meiring
Original Assignee
Staat Der Nederlanden Vert Doo
Els Cecile Antoinette Caro Van
Jong Adrianus Petrus Joseph De
Hugo Derk Meiring
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staat Der Nederlanden Vert Doo, Els Cecile Antoinette Caro Van, Jong Adrianus Petrus Joseph De, Hugo Derk Meiring filed Critical Staat Der Nederlanden Vert Doo
Publication of WO2005023295A2 publication Critical patent/WO2005023295A2/fr
Publication of WO2005023295A3 publication Critical patent/WO2005023295A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des peptides immunodominants traités naturellement et identifiés avec précision, lesquels peptides sont dérivés du sérotype B de N. meningitidis et peuvent être utilisés pour le diagnostic ex vivo de réponses immunitaires restreintes humaines du CMH de classe II aux antigènes méningococciques. Ces peptides immunodominants naturellement présents sont hautement immunogènes in vivo et sont capables de rappeler une réponse ex vivo des cellules CD4+T spécifiques de l'antigène. Les peptides immunodominants dérivés de la protéine PorA peuvent également être utilisés dans des procédés de vaccination contre le sérotype B de N. Meningitidis.
PCT/NL2004/000626 2003-09-10 2004-09-10 Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation WO2005023295A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077849.2 2003-09-10
EP03077849 2003-09-10

Publications (2)

Publication Number Publication Date
WO2005023295A2 WO2005023295A2 (fr) 2005-03-17
WO2005023295A3 true WO2005023295A3 (fr) 2005-09-29

Family

ID=34259181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2004/000626 WO2005023295A2 (fr) 2003-09-10 2004-09-10 Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation

Country Status (1)

Country Link
WO (1) WO2005023295A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1943269A2 (fr) * 2005-10-14 2008-07-16 Intercell AG Antigenes de neisseria meningitidis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849275A1 (fr) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Peptides mannosylés
WO2000003003A2 (fr) * 1998-07-10 2000-01-20 The University Of Nottingham Criblage de candidats-vaccins antineisseria et vaccins contre une neisseria pathogene
WO2002083711A2 (fr) * 2001-04-17 2002-10-24 Chiron Corporation Mimetiques moleculaires d'epitopes b meningococciques qui elicitent des anticorps fonctionnellement actifs
EP1288292A1 (fr) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Peptide longs comprenant 22-40 acides aminés et induisant ou augmentant une réponse immuntaire spécifique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849275A1 (fr) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Peptides mannosylés
WO2000003003A2 (fr) * 1998-07-10 2000-01-20 The University Of Nottingham Criblage de candidats-vaccins antineisseria et vaccins contre une neisseria pathogene
WO2002083711A2 (fr) * 2001-04-17 2002-10-24 Chiron Corporation Mimetiques moleculaires d'epitopes b meningococciques qui elicitent des anticorps fonctionnellement actifs
EP1288292A1 (fr) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Peptide longs comprenant 22-40 acides aminés et induisant ou augmentant une réponse immuntaire spécifique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DELVIG A.A. ET AL.: "T-cell epitope mapping the PorB protein of serogroup B Neisseria meningitidis in B10 congenic strains of mice.", CLIN. IMMUN. IMMUNOPATH., vol. 85, no. 2, November 1997 (1997-11-01), pages 134 - 142, XP002266485 *
DERRICK J.P. ET AL.: "Structural and evolutionary inference from molecular variation in Neisseria porins.", INFECT. IMMUN., vol. 67, no. 5, May 1999 (1999-05-01), pages 2406 - 2413, XP002266483 *
VAN DER LEY P. ET AL.: "Topology of outer membrane porins in pathogenic Neisseria Spp..", INFECT. IMMUN., vol. 59, no. 9, September 1991 (1991-09-01), pages 2963 - 2971, XP000946494 *
VERMONT C. ET AL.: "Neisseria meningitidis serogroup B : laboratory correlates of protection.", FEMS IMMUN. MED. MICROB., vol. 34, 2002, pages 89 - 96, XP002266484 *
WIERTZ E.J.H.J. ET AL.: "Identification of T cell epitopes occuring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.", J. EXP. MED., vol. 176, July 1992 (1992-07-01), pages 79 - 88, XP002266481 *
WIERTZ E.J.H.J. ET AL.: "Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements.", J. IMMUNOL., vol. 147, no. 6, 15 September 1991 (1991-09-15), pages 2012 - 2018, XP000986185 *
WIERTZ E.J.H.J. ET AL.: "T-cell responses to outer membrane proteins of Neisseria meningitidis : Comparative study of the Opa, Opc, and PorA proteins.", INFECT. IMMUN., vol. 64, no. 1, January 1996 (1996-01-01), pages 298 - 304, XP002127427 *

Also Published As

Publication number Publication date
WO2005023295A2 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
EP2181714A3 (fr) Composition immunogène pour la vaccination contre des staphylocoques
CR10123A (es) Vacuna.
TW200722101A (en) Novel composition
EP1897555A3 (fr) Vaccin OMV complété contre la méningocoque
WO2005037190A3 (fr) Vaccins multiplex
GB2434367A (en) Improved vaccines
WO2007026249A3 (fr) Vaccination multiple comprenant des meningocoques du serogroupe c
WO2008112344A3 (fr) Matériaux de matrice extracellulaires comme adjuvants de vaccin pour maladies associées à des toxines ou à des pathogènes infectieux
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
WO2009039854A8 (fr) Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
EP2462949A3 (fr) Formulations de vaccins contre les méningocoques
WO2007016185A3 (fr) Conjugues anticorps monofonctionnels ou bifonctionnels en tant qu'adjuvants efficaces de vaccination proteique
WO2006004390A3 (fr) Methode de preparation et d'utilisation d'un vaccin bivalent contre la dependance a la morphine/heroine
EP2302033A3 (fr) Identification des régions RD1 et RD5 associées avec la virulence permettant le développement des vaccins améliorés de M. bovis BCG et M. microti
WO2021247715A3 (fr) Antigènes immunogènes de francisella et leur utilisation dans l'immunisation de poissons contre la francisellose
WO2006072787A8 (fr) Compositions permettant d'immuniser contre mycobacterium
WO2005000884A8 (fr) Conjugues d'acide poly-gamma-glutamique pour solliciter des reponses immunitaires dirigees contre des bacilles
ZA200706389B (en) Compositions for immunizing against mycobacterium
WO2003083083A3 (fr) Procedes d'utilisation d'un ligand flt3 dans des protocoles d'immunisation
WO2005007804A3 (fr) Vaccin conjugue contre l'anthrax et anticorps diriges contre des bacilles et des toxines de l'anthrax
MX2023009728A (es) Vacuna recombinante meningococica b.
WO2005023295A3 (fr) Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation
Van Den Dobbelsteen et al. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine
Norheim et al. Prevention of serogroup A, C and W135 meningococcal disease in Africa with outer membrane vesicle vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase